Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 1
1953 1
1954 2
1956 2
1958 2
1959 4
1960 4
1961 4
1962 3
1963 6
1964 10
1965 5
1966 12
1967 4
1968 5
1969 6
1970 11
1971 7
1972 9
1973 7
1974 12
1975 12
1976 7
1977 8
1978 5
1979 9
1980 7
1981 3
1982 4
1984 4
1985 4
1986 5
1987 3
1988 4
1989 2
1990 3
1991 2
1992 5
1994 9
1995 8
1996 3
1997 6
1998 7
1999 5
2000 4
2001 5
2002 3
2003 3
2004 2
2005 10
2006 9
2007 6
2008 13
2009 12
2010 18
2011 20
2012 19
2013 8
2014 2
2015 8
2016 6
2017 6
2018 5
2019 11
2020 11
2021 14
2022 13
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

438 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Among authors: orloff m. Ann Surg Oncol. 2024 May 4. doi: 10.1245/s10434-024-15293-x. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38704501
Coronavirus disease 2019-related hepatic transplant pseudoaneurysm.
Kapoor S, Tomiyama K, Orloff MS, Sharma AK. Kapoor S, et al. Among authors: orloff ms. J Vasc Surg Cases Innov Tech. 2024 Mar 4;10(3):101469. doi: 10.1016/j.jvscit.2024.101469. eCollection 2024 Jun. J Vasc Surg Cases Innov Tech. 2024. PMID: 38577692 Free PMC article.
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM, Watkins C, Costa-García M, Del Carpio L, Piperno-Neumann S, Rutkowski P, Hassel JC, Espinosa E, de la Cruz-Merino L, Ochsenreither S, Shoushtari AN, Orloff M, Salama AKS, Goodall HM, Baurain JF, Nathan P. Piulats JM, et al. Among authors: orloff m. Ann Oncol. 2024 Mar;35(3):317-326. doi: 10.1016/j.annonc.2023.11.013. Epub 2023 Dec 2. Ann Oncol. 2024. PMID: 38048850 Free article. Clinical Trial.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, Sacco JJ, Ochsenreither S, Joshua AM, Gastaud L, Curti B, Piulats JM, Salama AKS, Shoushtari AN, Demidov L, Milhem M, Chmielowski B, Kim KB, Carvajal RD, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Nathan P. Hassel JC, et al. Among authors: orloff m. N Engl J Med. 2023 Dec 14;389(24):2256-2266. doi: 10.1056/NEJMoa2304753. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870955 Clinical Trial.
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA).
Wei AZ, Chen LN, Orloff M, Ariyan CE, Asgari M, Barker CA, Buchbinder E, Chandra S, Couts K, Frumovitz MM, Futreal A, Gershenwald JE, Hanna EY, Izar B, LeBlanc AK, Leitao MM Jr, Lipson EJ, Liu D, McCarter M, McQuade JL, Najjar Y, Rapisuwon S, Selig S, Shoushtari AN, Yeh I, Schwartz GK, Guo J, Patel SP, Carvajal RD. Wei AZ, et al. Among authors: orloff m. Pigment Cell Melanoma Res. 2023 Nov;36(6):542-556. doi: 10.1111/pcmr.13139. Epub 2023 Oct 7. Pigment Cell Melanoma Res. 2023. PMID: 37804122
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O, Hassel JC, Shoushtari AN, Meier F, Bauer TM, Salama AKS, Kirkwood JM, Ascierto PA, Lorigan PC, Mauch C, Orloff M, Evans TRJ, Holland C, Edukulla R, Abedin SE, Middleton MR. Hamid O, et al. Among authors: orloff m. J Immunother Cancer. 2023 Jun;11(6):e006747. doi: 10.1136/jitc-2023-006747. J Immunother Cancer. 2023. PMID: 37286303 Free PMC article. Clinical Trial.
438 results